전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
alemtutsumabi
alemtuzumab
마지막 업데이트: 2014-11-21
사용 빈도: 4
품질:
mabcampath alemtutsumabi
mabcampath alemtuzumab
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
vaikuttava aine on alemtutsumabi.
the active substance is alemtuzumab.
마지막 업데이트: 2017-04-26
사용 빈도: 4
품질:
ei tiedetä, erittyykö alemtutsumabi ihmisen rintamaitoon.
it is unknown whether alemtuzumab is excreted in human milk.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
lemtrada 12 mg infuusiokonsentraatti, liuosta varten alemtutsumabi
lemtrada 12 mg concentrate for solution for infusion alemtuzumab
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
lemtrada 12 mg steriili konsentraatti alemtutsumabi i.v.
lemtrada 12 mg sterile concentrate alemtuzumab
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
mabcampath 10 mg/ml infuusiokonsentraatti, liuosta varten alemtutsumabi
mabcampath 10 mg/ml concentrate for solution for infusion alemtuzumab
마지막 업데이트: 2017-04-26
사용 빈도: 14
품질:
mabcampath 10 mg/ml, infuusiokonsentraatti, liuosta varten alemtutsumabi
mabcampath 10 mg/ml concentrate for solution for infusion
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
mabcampath 10 mg/ ml infuusiokonsentraatti, liuosta varten alemtutsumabi laskimoon
mabcampath 10 mg/ ml concentrate for solution for infusion alemtuzumab intravenous use
마지막 업데이트: 2012-04-10
사용 빈도: 4
품질:
mabcampath-valmisteen vaikuttava aine, alemtutsumabi, on monoklonaalinen vasta-aine.
the active substance in mabcampath, alemtuzumab, is a monoclonal antibody.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
alemtutsumabi--valmisteella ei ole relevanttia käyttötarkoitusta alle 10-vuotiailla lapsipotilailla multippeliskleroosin hoidossa.
there is no relevant use of alemtuzumab in children aged from birth to less than 10 years for the treatment of multiple sclerosis.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
ihmisen igg:n tiedetään läpäisevän istukan; myös alemtutsumabi voi läpäistä istukan ja siten mahdollisesti aiheuttaa riskin sikiölle.
human igg is known to cross the placental barrier; alemtuzumab may cross the placental barrier as well and thus potentially pose a risk to the foetus.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
potilaille, joille kehittyi alemtutsumabi-vasta-aineita, kehittyi niitä 15 kuukauteen mennessä hoidon aloituksen jälkeen.
patients who developed anti-alemtuzumab antibodies did so by 15 months from initial exposure.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
alemtutsumabi on tuotettu siirtämällä kuusi komplementaarisuudesta vastaavaa aluetta rotan monoklonaalisesta igg2a-vasta-aineesta humaaniin igg1- immunoglobuliinimolekyyliin.
alemtuzumab was generated by the insertion of six complementarity-determining regions from an igg2a rat monoclonal antibody into a human igg1 immunoglobulin molecule.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
alemtutsumabi on yhdistelmä-dna-tekniikalla nisäkässolususpensioviljelmässä (kiinanhamsterinmunasarjasolut) - ravintoaineliuoksessa tuotettu monoklonaalinen vasta-aine.
alemtuzumab is a monoclonal antibody produced in mammalian cell (chinese hamster ovary) suspension culture in a nutrient medium by recombinant dna technology.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
yksi injektiopullo sisältää 30 mg alemtutsumabia
each vial contains 30 mg of alemtuzumab.
마지막 업데이트: 2017-04-26
사용 빈도: 6
품질: